News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 139
- Sources here
- 14
- Companies here
- 5
Search results
Stored financial headlines
Active search
139 matching headlines
Ticker or company: INTSMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Intensity Therapeutics has restarted patient treatment in its Phase 2 INVINCIBLE-4 Study for triple-negative breast cancer (TNBC) in Switzerland, after a temporary pause to address skin irritation issues. The trial, using INT230-6 before standard-of-care immunotherapy-chemotherapy, aims to improve pathological complete response rates in patients …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics (INTS) AGM 2026 Summary
The Intensity Therapeutics (INTS) 2026 Annual General Meeting (AGM) was held virtually on June 16, 2026, at 10:30 AM ET. Key proposals included the re-election of two directors, ratification of EisnerAmper LLP as auditors, and amendments to the 2021 Stock Incentive Plan and 2024 …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics (INTS) Q4 2025 earnings summary
Intensity Therapeutics (INTS) reported its Q4 2025 earnings, highlighting a cash balance of $11.9 million at year-end, providing a cash runway into Q2 2027. The company raised over $20 million in gross proceeds in 2025 and saw reduced R&D and G&A expenses, leading to …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics resumes patient dosing in Swiss trial
Intensity Therapeutics Inc. has resumed patient dosing in its INVINCIBLE-4 Study in Switzerland for early-stage, operable triple-negative breast cancer, following a temporary pause due to skin irritation. The company's stock has faced volatility, but analysts maintain a bullish outlook, with InvestingPro suggesting it is …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%
Intensity Therapeutics restarts 61-patient breast cancer trial
Intensity Therapeutics has restarted its INVINCIBLE-4 trial for breast cancer after pausing due to skin irritation. The company will now recruit an additional 47 patients in Switzerland and France using an amended single-injection protocol. Preliminary results from the first 14 patients show promising pathological …
INTS
main company
Sharemaestro market context
Price below Trend Line
52 weeks -47.9% · Next-week setup negative 38.9%